Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

257
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
257
Global Climate Change01:50

Global Climate Change

28.9K
Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.
28.9K
Introduction to Global Positioning System01:30

Introduction to Global Positioning System

505
The Global Positioning System (GPS) revolutionized positioning on Earth, providing precise location data through satellite ranging. The GPS system was developed in 1978 by the U.S. Department of Defense  for military use, and it became available for civilian applications in 1983, transforming fields including navigation, fleet management, and time synchronization for telecommunications systems.GPS consists of satellites in medium Earth orbit, about 20,200 kilometers above the surface,...
505
Errors in Global Positioning System01:26

Errors in Global Positioning System

348
Global Positioning System (GPS) technology has revolutionized navigation and positioning, but its accuracy is often compromised by various errors. These errors, stemming from environmental, satellite, and receiver-related factors, require careful mitigation to ensure reliable performance across applications.Atmospheric ErrorsGPS signals travel through the Earth’s ionosphere and troposphere, introducing delays which affect accuracy. The ionosphere is strongly influenced by charged particles,...
348
Global Regulatory Systems01:28

Global Regulatory Systems

660
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
660
Field Application of Global Positioning System01:28

Field Application of Global Positioning System

326
The Global Positioning System (GPS) has become an indispensable tool in fieldwork, offering unparalleled precision and efficiency for surveying, navigation, and infrastructure development. By harnessing signals from a constellation of satellites, GPS receivers determine the location of objects with remarkable speed and accuracy, often completing calculations within a second.Advantages of Modern GPS TechnologyContemporary GPS receivers are designed to meet the practical demands of field...
326

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Risankizumab: First Global Approval.

Drugs·2019
Same author

<i>Ginkgo biloba</i> extract EGb 761<sup>®</sup> in the symptomatic treatment of mild-to-moderate dementia: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.

Clinical drug investigation·2017
Same author

Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.

CNS drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jan 29, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.6K

Ravulizumab: First Global Approval.

Kate McKeage1

  • 1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 16, 2019
PubMed
Summary
This summary is machine-generated.

Ravulizumab, a C5 complement inhibitor, is approved for paroxysmal nocturnal haemoglobinuria (PNH). It prevents cell lysis by inhibiting the C5b-9 complex, offering a new treatment option for PNH patients.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K

Related Experiment Videos

Last Updated: Jan 29, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.6K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K

Area of Science:

  • Immunology
  • Pharmacology
  • Hematology

Background:

  • Ravulizumab is a humanized monoclonal antibody targeting complement C5.
  • It functions similarly to eculizumab by inhibiting the terminal complement complex C5b-9.
  • This mechanism prevents the cell lysis characteristic of complement-mediated disorders.

Purpose of the Study:

  • To summarize the developmental milestones of ravulizumab.
  • To highlight its first global approval for paroxysmal nocturnal haemoglobinuria (PNH).

Main Methods:

  • Development of ravulizumab utilizing Xencor's Xtend™ antibody half-life prolongation technology.
  • Clinical trials for PNH, atypical haemolytic uraemic syndrome (aHUS), myasthenia gravis, and IgA nephropathy.
  • Evaluation of subcutaneous formulation and coadministration with Halozyme's ENHANZE® technology.

Main Results:

  • Ravulizumab received its first global approval in the USA in December 2018 for adult PNH treatment.
  • Regulatory reviews are ongoing in the EU and Japan for PNH.
  • Phase 3 trials for aHUS are in progress worldwide.

Conclusions:

  • Ravulizumab represents a significant advancement in complement inhibition therapy.
  • Its development signifies progress in treating PNH and potentially other complement-mediated diseases.
  • Ongoing research into extended half-life formulations and delivery methods promises improved patient convenience.